Skip to content

Study · Systematic review · n = 6,028 · 2022

4 results

Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials.

Lin Q, Xue Y, Zou H, Ruan Z, Ung COL, Hu H

Expert review of clinical pharmacology5 Oct 2022Cited by 16 (Europe PMC)

PMID36180402 (opens in a new tab)DOI10.1080/17512433.2022.2130760 (opens in a new tab)PepBankPUB-36180402
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with obesity or overweight, a meta-analysis of seven RCTs found that liraglutide 3.0 mg reduced body weight by 4.81% more than placebo.

    In plain wordsIn adults with obesity or overweight, liraglutide 3.0 mg led to more weight loss than placebo in pooled trials.

    Peptide
    Liraglutide
    Outcome
    DecreasePercentage weight change
    Study

    n = 6,028

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mg · at least 1 yearAs given in this study (human).

    Measurements

    Mean difference in percentage weight change
    −4.81%
    liraglutide 3.0 mg vs placebo

    Source sentences

    Summary
    Meta-analyses of seven phase 3 and 4 RCTs (N = 6,028), which were conducted in adults with obesity or overweight for at least 1 year, demonstrated a significant weight reduction with liraglutide 3.0 mg (mean difference of percentage weight change -4.81%; 95% CI: -5.56% to -4.06%; P < 0…
  2. 02HumanSystematic reviewSafety outcome

    In adults with obesity or overweight, more participants on liraglutide 3.0 mg had at least one adverse event.

    In plain wordsIn adults with obesity or overweight, more people taking liraglutide had at least one side effect.

    Peptide
    Liraglutide
    Outcome
    IncreaseParticipants with at least one adverse event
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    However, more participants taking liraglutide experienced at least one adverse event.
    1 context sentence
    Summary · context
    Meta-analyses of seven phase 3 and 4 RCTs (N = 6,028), which were conducted in adults with obesity or overweight for at least 1 year, demonstrated a significant weight reduction with liraglutide 3.0 mg (mean difference of percentage weight change -4.81%; 95% CI: -5.56% to -4.06%; P < 0…
  3. 03HumanSystematic reviewSafety outcome

    In adults with obesity or overweight, more participants on liraglutide 3.0 mg stopped treatment because of adverse events.

    In plain wordsIn adults with obesity or overweight, more people taking liraglutide stopped treatment because of side effects.

    Peptide
    Liraglutide
    Outcome
    IncreaseDiscontinuation due to adverse events
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    More discontinuations due to adverse events were observed among them.
    1 context sentence
    Summary · context
    Meta-analyses of seven phase 3 and 4 RCTs (N = 6,028), which were conducted in adults with obesity or overweight for at least 1 year, demonstrated a significant weight reduction with liraglutide 3.0 mg (mean difference of percentage weight change -4.81%; 95% CI: -5.56% to -4.06%; P < 0…
  4. 04HumanSystematic reviewEfficacy outcome

    In a subgroup analysis, liraglutide was linked to a greater decrease in percentage weight change in participants without diabetes than in those with diabetes.

    In plain wordsIn pooled trials, people without diabetes lost more weight on liraglutide than people with diabetes.

    Peptide
    Liraglutide
    Outcome
    DecreasePercentage weight change, subgroup without diabetes versus with diabetes
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    In the subgroup analysis among participants with or without diabetes mellitus (DM), pooled result showed that liraglutide was associated with a greater decrease in the percentage of weight change in participants without DM.
    1 context sentence
    Summary · context
    Meta-analyses of seven phase 3 and 4 RCTs (N = 6,028), which were conducted in adults with obesity or overweight for at least 1 year, demonstrated a significant weight reduction with liraglutide 3.0 mg (mean difference of percentage weight change -4.81%; 95% CI: -5.56% to -4.06%; P < 0…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.